Roche Moves Ahead with Possible Disease-Modifying Parkinson’s Drug

A new Parkinson’s drug that aims to slow the disease—not just mask the symptoms—is now moving into Phase III trials, according to pharmaceutical company Roche. The treatment, called prasinezumab, is a lab-made antibody designed to target alpha-synuclein, a protein that builds up in the brain and is believed to drive the progression of Parkinson’s. If successful, prasinezumab could become the first treatment of its kind that tackles the underlying biology of Parkinson’s, rather than just easing symptoms like tremor and stiffness. What’s different about prasinezumab? Most current Parkinson’s treatments focus on relieving symptoms by replacing or mimicking dopamine. But they don’t change the course of the disease itself. Prasinezumab takes a different approach. It’s a monoclonal antibody—a type of medicine that acts like a smart homing device. It’s designed to bind to clumps of alpha-synuclein in the brain and help clear them out or stop them spreading. These clumps are known to damage brain cells and are a key feature of Parkinson’s disease. By targeting alpha-synuclein early, prasinezumab aims to slow down the rate at which the disease progresses. Why is Roche moving into Phase III? Roche’s decision is based on the results of its Phase IIb PADOVA trial, which included 586 people with early-stage Parkinson’s. Everyone in the study was already on a stable Parkinson’s treatment (most commonly levodopa), and prasinezumab was added on top. While the trial just missed hitting its main statistical goal, the results still showed positive trends—especially among people taking levodopa. In that group, the drug appeared to delay motor progression, meaning people’s movement symptoms worsened more slowly than in those on a placebo. Over a two-year period, those on prasinezumab showed a 30–40% slower rate of progression compared to those on placebo. Importantly, people in the study have continued taking the drug in open-label extensions (where everyone knows they’re receiving the drug), with over 750 participants now involved. These follow-up studies suggest the benefits may continue or even improve over time. What about side effects? So far, prasinezumab has been well tolerated, with no major safety concerns reported. Roche now has safety data on over 900 people with Parkinson’s who have taken the drug—some for as long as five years. Why does this matter? This could be the first time a treatment is shown to modify the course of Parkinson’s, rather than just easing symptoms in the short term. That’s a big deal—especially for people in the early stages who want to preserve their function and independence for as long as possible. What’s next? Roche is now preparing to launch Phase III trials, which will involve a larger group of people and aim to confirm whether the drug works well enough to be approved for wider use. The company hasn’t announced a start date yet, but this is a major milestone and signals real confidence in the potential of the treatment. For the Parkinson’s community, this is promising news. While we still need to wait for the results of the next trial stage, prasinezumab could represent a new class of treatment—one that directly tackles what’s happening inside the brain, not just how it feels on the outside.